Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 537-545

  Vassal, G ^a   Terrier Lacombe, M J ^a   Bissery, M C ^b   Venuat A M ^a   Gyergyay, F ^a   Benard J ^a   Morizet, J ^a   Boland, I ^a   Ardouin, P ^a   Bressac de Paillerets, B ^a   Gouyette, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SANOFI   (France)

Author keywords

CPT 11; Neuroblastoma; Peripheral primitive neuroectodermal tumour; Xenograft

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; ETOPOSIDE; IRINOTECAN; PACLITAXEL; THIOTEPA; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; DIPLOIDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HISTOLOGY; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; TUMOR REGRESSION;

EID: 9444258554     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.398     Document Type: Article

References (37)

1. ABIGERGES D, CHABOT GG, ARMAND JP, HERAIT P, GOUYETTE A AND GANDIA D. (1995). Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13, 210 - 221.
2. BETTAN-RENAUD L, BAYLE C, TEYSSIER JR AND BENARD J (1989). Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835. Int. J. Cancer, 44, 460 - 466.
3. BIEDLER JL, HELSON L AND SPENGLER BA. (1973). Morphology and growth, tumorigenicity and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res., 33, 2643 - 2652.
4. BISSERY MC, MATHIEU-BOUE A AND LAVELLE F. (1992). Experimental antitumour activity of CPT-11 in vitro and in vivo. Ann. Oncol., 3 (suppl. 1), 82.
5. BOURHIS J, BENARD J, HARTMANN O, BOCCON-GIBOD L, LEMERLE J AND RIOU G. (1989). Correlation of MDRI gene expression with chemotherapy in neuroblastomas. J. Natl Cancer. Inst., 81, 1401 - 1405.
6. BOVEN E, WINOGRAD B, GODSTAD O, LOBBEZOO MW AND PINEDO HM. (1988). Preclinical phase II studies in human tumor lines: a european multicenter study. Eur. J. Cancer Clin. Oncol., 24, 567 - 573.
7. BRODEUR GM, SEEGER RC, SCHWAB M, VARMUS HE AND BISHOP JM. (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 224, 1121 - 1124.
8. CHAN H, HADDAD G, THORNER P, DEBOER G, PING LIN Y, ONDRUSEK N, YEGER H AND LING V. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med., 325, 1608 - 1614.
9. CHEN P, LIN HH AND WEISSMAN BE. (1995). A functional analysis of tumor suppressor activity for peripheral neuroepitheliomas by monochromosome transfer.Oncogene, 10, 577 - 586.
10. DELATTRE O, ZUCMAN J, PLOUGASTEL B, DESMAZE C, MELOT T, PETER M, KOVAR H, JOUBERT I, DE JONG P, ROULEAU G, AURIAS A AND THOMAS G. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumors. Nature, 359, 162 - 165.
11. DUTRILLAUX B AND LEJEUNE J. (1971). On a new technique of human karyotype study. CR Acad. Sci. Paris, 272, 2638 - 2640.
12. FERRANDIS E, DA SILVA J, RIOU G AND BENARD J. (1994). Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res., 554, 2256 - 2261.
13. FONG CT, DRACOPOLI NC, WHITE PS, MERRILL T, GRIFFITH RC, HOUSMAN DE AND BRODEUR GM. (1989). Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc. Natl Acad. Sci. USA, 86, 3753 - 3757.
14. FRIEDMAN HS, SCHOLD SC AND BIGNER DD. (1986). Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic mice. Cancer Res., 46, 224 - 228.
15. GEORGE BA, YANIK G, WELLS RJ, MARTIN LW, SOUKUP S, BALLARD ET, GARTSIDE PS AND LAMPKIN BC. (1993). Growth patterns of human neuroblastoma xenografts and their relationship to treatment outcome. Cancer, 73, 3331 - 3339.
16. HAYASHI Y, KANDA H, INABA T, HANADA R, NAGAHARA N, RUCHI H AND YAMAMOTO K. (1989). Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer, 63, 126 - 132.
17. HAYES FA, THOMPSON EL, MEYER WH, KUN L, PARHAM D, RAO B, KUMAR M, HANCOCK M, PARVEY L, MAGILL L AND HUST O. (1989). Therapy for localized Ewing's sarcoma of bone. J. Clin. Oncol., 7, 208 - 213.
18. HOUGHTON PJ, CHESCHIRE PJ, HALLMAN JC, BISSERY MC, MATHIEU-BOUE A AND HOUGHTON JA. (1993). Therapeutic activity of the topoisomerase I inhibitor 7-ethyl-10-(4[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53, 2823 - 2829.
19. HOUGHTON PJ, CHESCHIRE PJ, HALLMAN II JD, LUTZ L, FRIEDMAN HS, DANKS MK AND HOUGHTON JA. (1995). Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36, 393-403.
20. HSIANG YH, LIHOU LF AND LIU LF. (1989). Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49, 5077 - 5082.
21. HURWITZ CA, RELLING MW, WEITMAN SD, RAVINDRANATH Y, VIETTI TJ, STROTHER DR, RAGAD AH AND PRATT CB. (1993). Phase I trial of paclitaxel in children with refractory solid tumors. J. Clin. Oncol., 11, 2324 - 2329.
22. KAWATO Y, FURUTA T, AONUMIA M, YASUOKA M, YOKOKURA T AND MATSUMOTO K. (1991). Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28, 192 - 198.
23. KOMURO H, LI P, TSUCHIDA Y, YOKOMORI K, NAKAJIMA K, AOYAMA T, KANEDO M AND KANEDA N. (1994). Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med. Ped. Oncol., 23, 487 - 492.
24. KRETSCHMAR C, KLETZEL M, MURRAY K, JOSHI V, SMITH E, PAO R AND CASTLEBERRY R. (1995). Upfront phase II therapy with taxol and topotecan in untreated children (<365 days) with disseminated (INSS stage 4) neuroblastoma. A Pediatric Oncology Group study. Med. Ped. Oncol., 25, 243.
25. KUNG F, FAYES A, KRISHNER J, MAHONEY D, LEVENTHAL B, BRODEUR G, BERRY DH, DUBOWY R AND TOLEDANO S. (1988). Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. Invest. New Drugs, 6, 31 - 36.
26. KUNIMOTO T, NITTA K, TANAKA T, UEHARA N, BABA H, TAKEUCHI M, YOKOKURA T, SAWADA S, MIYASAKA T AND MUTAI M. (1987). Antitumor activity of 7-ethyl-10-(4[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944 - 5947.
27. KUSHNER BH, LAQUAGLIA MP, BONILLA MA, LJNDSLEY K, ROSENFIELD N, YEH S, EDDY J, GERALD WL, HELLER G AND CHEUNG NV. (1994). Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J. Clin. Oncol., 12, 2607 - 2613.
28. MASUDA N, FUKUOKA M, KUSUNOKI Y, MATSUI K, TAKIFUJI N, KUDOH S, NEGORO S, NISHIOKA M, NAKAGAWA K AND TAKADA M. (1992). CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10, 1225 - 1229.
29. MÉRESSE V, VASSAL G, MICHON J, DE CERVENS C, COURBON B, RUBIE H, PEREL Y, LANDMAN J, CHASTAGNIER P, DE VALCK C AND HARTMANN O. (1993). Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II from the Société Française d'Oncologie Pédiatrique. J. Clin. Oncol., 11, 630 - 637.
30. PHILIP T, GHALIE R, PINKERTON R, ZUCKER JM, BERNARD JL, LEVERGER G AND HARTMANN O. (1987). A phase II of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique. J. Clin. Oncol., 5, 941 - 950.
31. POMMIER Y, TANIZAWA A AND KOHN KW. (1994). Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Advances in Pharmacology, 29B, Liu LF (ed.), pp. 73 - 92. Academic Press Inc: San Diego.
32. POTMESIL M. (1994). Camptothecins: from bench research to hospital wards. Cancer Res., 54, 1431 - 1439.
33. TANIZAWA A, FUJIMORI A, FUJIMORI Y AND POMMIER Y. (1994). Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst., 86, 836 - 842.
34. TSURUO T, MATSUZAKI T, MATSUSHITA M, SAITO H AND YOKOKURA T. (1988). Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21, 71 - 74.
35. VASSAL G, MORIZET J, BISSERY MC, BOLAND I, ARDOUIN P, MATHIEU-BOUE A AND GOUYETTE A. (1994). Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblastoma xenografts. Proc. Am. Assoc. Cancer Res., 35, 366.
36. WINOGRAD B, LOBBEZOO MW AND PINEDO HM. (1988). Proposal for the application of xenografts in screening for new anticancer agents and in selecting tumor types for phase II clinical trials. In Human Tumor Xenografts in Anticancer Drug Development. Winograd B, Peckham MJ, Pinedo HM (eds), pp. 111 - 114. Springer: Berlin.
37. WOLFF SN, HERZIG RH, FAY JW, LEMAISTRE CF, BROWN RA, FREI-LAKR D, STRANJORD S, GIANNONE L, COCCIA P, WEICK JL, ROTHMAN SA, KRUPP KR, LOWDER J, BOLWELL B AND HERZIG GP. (1990). High-dose N,N′ N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin. Oncol., 17 (Suppl. 3), 2 - 6.